Paul J Clancy - Net Worth and Insider Trading
Paul J Clancy Net Worth
The estimated net worth of Paul J Clancy is at least $20 Million dollars as of 2023-03-28. Paul J Clancy is the EVP, CFO of Alexion Pharmaceuticals Inc and owns about 93,309 shares of Alexion Pharmaceuticals Inc (ALXN) stock worth over $17 Million. Paul J Clancy is also the Executive VP and CFO of Biogen Inc and owns about 10,813 shares of Biogen Inc (BIIB) stock worth over $3 Million. Details can be seen in Paul J Clancy's Latest Holdings Summary section.
Transaction Summary of Paul J Clancy
Paul J Clancy Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul J Clancy owns 6 companies in total, including Incyte Corp (INCY) , Agios Pharmaceuticals Inc (AGIO) , and Alexion Pharmaceuticals Inc (ALXN) among others .
Click here to see the complete history of Paul J Clancy’s form 4 insider trades.
Insider Ownership Summary of Paul J Clancy
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INCY | Incyte Corp | 2015-01-20 | director |
| AGIO | Agios Pharmaceuticals Inc | 2013-09-24 | director |
| ALXN | Alexion Pharmaceuticals Inc | 2019-07-11 | EVP & Chief Financial Officer |
| BIIB | Biogen Inc | 2008-09-04 | Executive VP and CFO |
| EXAS | Exact Sciences Corp | 2021-03-18 | director |
| XLO | Xilio Therapeutics Inc | 2021-10-21 | director |
Paul J Clancy Latest Holdings Summary
Paul J Clancy currently owns a total of 2 stocks. Among these stocks, Paul J Clancy owns 93,309 shares of Alexion Pharmaceuticals Inc (ALXN) as of July 10, 2018, with a value of $17 Million and a weighting of 85.34999999999999%. Paul J Clancy also owns 10,813 shares of Biogen Inc (BIIB) as of April 25, 2017, with a value of $3 Million and a weighting of 14.65%.
Latest Holdings of Paul J Clancy
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALXN | Alexion Pharmaceuticals Inc | 2018-07-10 | 93,309 | 182.50 | 17,028,893 |
| BIIB | Biogen Inc | 2017-04-25 | 10,813 | 270.25 | 2,922,213 |
Holding Weightings of Paul J Clancy
Paul J Clancy Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul J Clancy has made a total of 1 transactions in Alexion Pharmaceuticals Inc (ALXN) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Alexion Pharmaceuticals Inc is the sale of 5,241 shares on July 10, 2018, which brought Paul J Clancy around $687,148.
According to the SEC Form 4 filings, Paul J Clancy has made a total of 0 transactions in Biogen Inc (BIIB) over the past 5 years. The most-recent trade in Biogen Inc is the sale of 9,892 shares on April 25, 2017, which brought Paul J Clancy around $3 Million.
Insider Trading History of Paul J Clancy
- 1
Paul J Clancy Trading Performance
Paul J Clancy Ownership Network
Ownership Network List of Paul J Clancy
Ownership Network Relation of Paul J Clancy
Paul J Clancy Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Paul J Clancy is the director of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Paul J Clancy made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Paul J Clancy Mailing Address
Above is the net worth, insider trading, and ownership report for Paul J Clancy. You might contact Paul J Clancy via mailing address: C/o Biogen Idec Inc., 14 Cambridge Center, Cambridge Ma 02142.
